3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Fátima Cardoso, Eric P. Winer, D. Fenech et al.|Annals of Oncology|2016Cited by 2.1k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|Journal of Clinical Oncology|2017Cited by 1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2George W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|JAMA Oncology|2019Cited by 983
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*Abram Recht, David G. Pfister, Stephen B. Edge et al.|Journal of Clinical Oncology|2001Cited by 819
Triple-Negative Breast Cancer: Risk Factors to Potential TargetsBryan P. Schneider, Lisa A. Carey, Eric P. Winer et al.|Clinical Cancer Research|2008Cited by 456